CD33 and neoplasm: Tumor-derived TGF-β stimulated CD39 and CD73 expression in CD11b+CD33+ MDSC in tumor tissues and peripheral blood of NSCLC patients, thereby inhibiting activity of T cells and NK cells and protecting tumor cells from the cytotoxic effect of chemotherapy (267).